Ad
related to: claritin d dosage by weight gain recommendations by bmi
Search results
Results From The WOW.Com Content Network
Claritin-D, others: AHFS/Drugs.com: claritin-d: Routes of administration: By mouth: ATC code: ... During controlled clinical studies with the recommended dosage, ...
Loratadine, sold under the brand name Claritin among others, is a medication used to treat allergies. [5] This includes allergic rhinitis (hay fever) and hives . [ 5 ] It is also available in drug combinations such as loratadine/pseudoephedrine , in which it is combined with pseudoephedrine , a nasal decongestant . [ 5 ]
Desloratadine sold under the brand name Clarinex among others, is a tricyclic H 1 inverse agonist that is used to treat allergies.It is an active metabolite of loratadine. [6]It was patented in 1984 and came into medical use in 2001. [7]
The corpulence index yields valid results even for very short and very tall persons, [7] which is a problem with BMI — for example, an ideal body weight for a person 152.4 cm tall (48 kg) will render BMI of 20.7 and CI of 13.6, while for a person 200 cm tall (99 kg), the BMI will be 24.8, very close to the "overweight" threshold of 25, while ...
For premium support please call: 800-290-4726 more ways to reach us
Other common adverse effects in first-generation H 1-antihistamines include dizziness, tinnitus, blurred vision, euphoria, incoordination, anxiety, increased appetite leading to weight gain, insomnia, tremor, nausea and vomiting, constipation, diarrhea, dry mouth, and dry cough.
In single-dose scenarios, the patient's body weight and the drug's recommended dose per kilogram are used to determine a safe one-time dose. If multiple doses of treatment are needed in a day, the physician must take into account information regarding the total amount of the drug which is safe to use in one day, and how that should be broken up ...
Classically, for clinical indications of an approved drug, TI refers to the ratio of the dose of the drug that causes adverse effects at an incidence/severity not compatible with the targeted indication (e.g. toxic dose in 50% of subjects, TD 50) to the dose that leads to the desired pharmacological effect (e.g. efficacious dose in 50% of ...